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I N THE CURRENT era of transplantation. the limitation 
of the cadaveric donor pool has necessitated a re-
evaluation of donor criteria to include organs that were 
previously considered high risk. The number of patients on 
the waiting list for all organs has since increased by 22% per 
year so that by the end of 1995, a total of 44,000 patients 
were registered (13,000 extrarenal and 31,000 renal).1 Con-
currently, deaths on the waiting list have increased by 18% 
per year while the total number of transplantations has only 
increased by 8% per year. In 1996, 13,000 kidney trans-
plants were performed in the United States and 934 in 
Canada. Simultaneously, the number of cadaveric organ 
donors has remained relatively static, with only a 4% 
increase per year from 1988 to 1994. Most of this incremen-
tally small increase has been through the use of "expanded" 
donors, reflected by the fact that the use of donors older 
than 50 years old increased by 24% per year from 1988 to 
1994, while those younger than 50 years increased by only 
1.5% per year. In 1996, there were a total of 4,500 cadaveric 
donors in the United States and 450 in Canada, represent-
ing a donor rate of approximately 15 per million population, 
which has been static since 19872•3 despite estimates of 
potential organ donor rates of up to 50 per million popu-
lation. A large study of the characterization of the potential 
renal organ donor pool in Pennsylvania concluded that the 
current ratio of organ donation could be increased by at 
least a factor of 2.4 To increase the potential donor supply, 
the implementation of presumed consent and financial 
incentives for donation have been proposed. In the United 
States, public attitude towards organ donation is such that 
presumed consent would probably not be acceptable. There 
has been resistance to financial incentives to the donor 
family because of the perceived danger of this escalating to 
the selling of organs as currently takes place in Southeast 
Asia and India. Efforts to expand the donor pool in this 
country are therefore limited to expanding the criteria for 
the use of "suboptimal" organs. This group would include 
kidneys from young (younger than 5 years old) pediatric 
donors, older donors, donors testing positive for hepatitis C 
antibody (HCV +), diabetic and hypertensive donors, and 
nonheartbeating donors (NHBD). 
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THE PEDIATRIC DONOR 
In a report from the UCLA Transplant Registry, kidneys 
from donors younger than 10 years old accounted for less 
than 10% of first cadaver donor kidneys between 1984 and 
1989.5 There has been no significant increase in this utili-
zation rate during the last 10 years. Overall, kidneys from 
donors aged 1 to 5 years had the lowest graft survival rate 
(68% at 1 year) followed by donors aged 6 to 10 years 
(70%) compared to the best survival rate (81%) using 
kidneys from donors aged 16 to 18 years.s As recently as 
1990, very poor survival rates of kidneys from donors 
younger than 3 years have been reported, with only a 40% 
I-year graft survival from donor kidneys aged 13 months to 
3 years and an extremely poor 19% I-year graft survival 
using donors younger than 1 year.a Other studies have 
recommended that even older pediatric donors (younger 
than 10 years) should not be used.7 Despite these appar-
ently dismal results with young pediatric donors, several 
institutions, including our own, have used these kidneys 
with success rates approaching those of adult donor kid-
neys. Pediatric donor kidneys may be used as single units or 
transplanted en bloc. We have used the en bloc approach to 
transplant pediatric kidneys from cadaveric donors younger 
than the age of 5 years.8•9 In our most recent published 
experience,IO recipients of pediatric en bloc kidneys, when 
compared with recipients of adult cadaveric kidneys, have 
comparable 1- and 3-year patient survival rates (94% and 
94% versus 95% and 91 %, respectively) and comparable l-
and 3-year graft survival rates (84% and 84% versus 89% 
and 79%, respectively). Renal function was better in recip-
ients of en bloc kidneys, with a mean serum creatinine 
(SCR) level of 1.4 ::: 1.8 mg/dL versus 2.0::: 1.5 mg/dL (P = 
.01). Overall, growth and development of pediatric en bloc 
kidneys is excellent. A doubling of renal size is usually 
found within the first 3 months after transplanta~ion on 
radiologic examination with significant improvement in 
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calculated glomerular filtration rates (G FR).1O·11 Some 
investigators have preferred to transplant kidneys from very 
young pediatric donors as single units. Lippman et al used 
single kidneys from donors aged 11 to 48 months in 50 
cases. 12 One-year graft survival was reported at 71 % com-
pared with 76% in recipients of adult donor kidneys at the 
same institution. Other investigators who have used single 
pediatric kidneys have reported I-year graft survival rates of 
84%.13 Regardless of the method of transplanting these 
small kidneys, it has become clear that excellent graft 
survival rates may be achieved. These organs are an unde-
rused resource that could have a significant impact on 
increasing the donor pool. 
THE OLDER DONOR 
Reluctance to use kidneys from older donors is based on 
the structural changes in the aging kidney including loss of 
glomeruli. reduction of glomerular surface area, overall 
reduction of functional renal mass. as well as obliteration of 
cortical vessels and spiraling of medullary arterioles with 
resulting functional changes in renal blood flow, GFR, and 
concentrating capacity.14 These structural changes are not 
universal and may not occur in all donors. Therefore, at our 
center we no longer place a strict upper age limit for 
cadaveric renal donors. We evaluate each donor individu-
ally on the basis of the available medical history and renal 
function. including SCR and 4-hour creatinine clearance 
during the period immediately preceeding organ recovery. 
Open renal biopsy with frozen section examination are 
performed for donors older than 50 years or with a history 
of significant hypertension. The kidney is generally used if 
there are fewer than 20o/c sclerotic glomeruli and if the 
degree of interstitial fibrosis is mild or less. In an earlier 
study from our institution. Vivas et al 15 found that in 31 
cadaver kidneys from donors older than 60 years of age, 
I-year graft survival was 65%; however. those kidneys that 
had a cold ischemia time (CIT) of more than 48 hours had 
a much inferior graft survival of 38'7c compared to those 
kidneys with CIT less than 48 hours, which had a very 
acceptable 76% I-year graft survival. In our most recent 
experience 10 with donors older than 60 years of age, 
compared with donors younger than 60 years of age, we 
observed worse 1- and 3-year patient survival rates (88% 
and 80% versus 96% and 94%. respectIvely. P < .03) and 
poorer 1- and 3-year graft survival rates (74'1 and 620 
versus Ii I '1c and 83%. respectivdy; P < .UOOl). Renal 
function was also decreased in the older group, with an 
SCR level of 2.7 ::: 1.2 mg;dL versus 1.9 ::: 1.5 mg/dL (P = 
.(1). The functional reserve of such older donor kidneys 
may he limited and hence any increased insult including 
prolonged CIT. nephrotoxic drug injury. or rejection may 
limit the eventual outcome. We have also n:cently hegun 
using "expanded" pancreas donors (older than 45 years 
and/or vasopressor support) with acceptahle results. 1" It has 
recent Iv heen proposed that older donor kidnevs that would 
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othelWise be discarded can be used as double organs,17 but 
long-term outcome is still unknown. 
THE HYPERTENSIVE AND DIABETIC DONOR 
Madden reported 88 patients who received cadaveric kid-
neys from donors with a history of either diabetes or 
hypertension ("non-ideal") were compared to 440 recipi-
ents of "ideal" organs. II! Although the overall graft survival 
of the non-ideal organs was somewhat less (69% versus 
74%), these differences were not significant. Again, these 
kidneys should be evaluated on an individual basis by biopsy 
and donor history. 
FEMALE DONORS 
Female donors have been associated with inferior graft 
survival after renal transplantation. In our experience,lO 
female donor kidneys, compared with male donors, are 
associated with comparable 1- and 3-year patient survival 
rates (96% and 93% versus 95% and 920£;. respectively) and 
comparable 1- and 3-year graft survival rates (90% and 80% 
versus 88% and 81 %, respectively). Renal function was also 
similar. 
THE DONOR WITH HEPATITIS C 
The use of the hepatitis C (HCY) + donor organ is contro-
versial and is a subject of ongoing current debate. Preva-
lence of HCY positivity in organ donors has been reported 
to be between 2% and 6% with contradictory data with 
respect to the risk of transmission of HCV from positive 
organ donors. Some of this confusion may have arisen from 
the methods of detection of HCY positivity, which in many 
early studies relied on a first generation assay with a 
significant false-positive rate. Pereira et al 19 showed that 
75% of seropositive donors transmitted HCY to the trans-
plant recipient. In contrast. Vincenti et al.10 found that six 
of seven transplant recipients who were seronegative before 
transplantation did not show any evidence of detectable 
HCY infection after transplantation with HCY + organs. In 
HCY + recipients of HCV + kidneys. the Mendez group 
reported a low (16%) incidence of liver dysfunction which 
was reversible in half of the patients with no adverse impact 
on patient or grafts survival.11 However. seroconversion was 
observed in 59% of HCV- recipients of HCY + organs. A 
similar transmission rate of 56% was noted by Tesi in 43 
patientsY Because of conflicting data. no uniform policy 
regarding the use of the HCV + kidney can currently be 
recommended. At our own institution. (urrent policy is to 
use HCY + organs in HCV + recipients if the donor liver 
biopsy is normal. To date. no patient transplanted at our 
institution under these guidelines has developed chronic 
liver disease; however, the follow-up is (urrently too short 
to draw any final conclusions. 
THE "ANATOMICALLY CHALLENGED" KIDNEY 
Techniljues of reconstructing kidneys with multiple or 
transected vcssels due to organ reCOVCT\' injury have been 
a 
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well described. 23 We have recently successfully transplanted 
a kidney that had undergone a one-thIrd surgical amputa-
tion (upper pole) and another kidney that had been previ-
ously transplanted 5 years earlier (reuse of the transplant 
kidney). Although these examples represent extreme situa-
tions. they show additional means for expanding the donor 
pool. 
NHBD 
The use of NHBD has been increasmg in the Linited States 
in recent years. and is commonplace in Japan. which has no 
legal brain death laws. NHBD kidneys. in both the con-
trolled and uncontrolled donor result in delayed graft 
function in 60% to 80% of cases. but are generally associ-
ated with acceptable graft survival rates. 24 
SUMMARY 
Advances in the surgical techniques. preservation solutions. 
and methods for predicting eventual long-term renal func-
tion from expanded donors will be critical in allowing 
precise selection criteria for kidneys for transplantation. 
resulting in the optimum use of a scarce and precious 
resource. Until other options such as xenotransplantation 
or tissue engineering become realistIC. the challenge for the 
millennium will be to identify which donor organs previ-
ously considered suboptimal (an be safely used to expand 
the organ donor pool. 
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